Overexpression of activated protein C hampers bacterial dissemination during pneumococcal pneumonia

BMC Infectious Diseases

Volumn 14, Issue 1, 2014, Pages

  de Boer, Johannes Daan ^a   Kager, Liesbeth M ^a,e   Roelofs, Joris J T H ^a   Meijers, Joost C M ^a,b   de Boer, Onno J ^a   Weiler, Hartmut ^c   Isermann, Berend ^d   van't Veer, Cornelis ^a   van der Poll, Tom ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b Department Plasma Proteins ^*  (Netherlands)

^c BLOOD RESEARCH INSTITUTE   (United States)

^d OTTO VON GUERICKE UNIVERSITY   (Germany)

^e UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Activated protein C; Coagulation; Inflammation; Neutrophils; Pneumonia

Indexed keywords

ACTIVATED PROTEIN C; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12P70; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; TUMOR NECROSIS FACTOR; PROTEIN C;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL LOAD; BLOOD CLOTTING; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; HISTOPATHOLOGY; HOST RESISTANCE; LIVER; LUNG HOMOGENATE; LUNG LAVAGE; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PROTECTION; PROTEIN EXPRESSION; SPLEEN; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE; SURVIVAL RATE; ANIMAL; C57BL MOUSE; DISEASE MODEL; GERMFREE ANIMAL; METABOLISM; MICROBIOLOGY; PATHOGENICITY;

ANIMALS; BACTERIAL LOAD; DISEASE MODELS, ANIMAL; FEMALE; LIVER; MICE; MICE, INBRED C57BL; PNEUMONIA, PNEUMOCOCCAL; PROTEIN C; SPECIFIC PATHOGEN-FREE ORGANISMS; SPLEEN; STREPTOCOCCUS PNEUMONIAE;

EID: 84920825153     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/s12879-014-0559-3     Document Type: Article

References (38)

1. Mizgerd JP: Acute lower respiratory tract infection. N Engl J Med 2008, 358:716-727.
2. van der Poll T, Opal SM: Pathogenesis, treatment, and prevention of pneumococcal pneumonia. Lancet 2009, 374:1543-1556.
3. Laterre PF, Garber G, Levy H, Wunderink R, Kinasewitz GT, Sollet JP, Maki DG, Bates B, Yan SC, Dhainaut JF: Severe community-acquired pneumonia as a cause of severe sepsis: data from the PROWESS study. Crit Care Med 2005, 33:952-961.
4. Bartlett JG, Dowell SF, Mandell LA, File TM Jr, Musher DM, Fine MJ: Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America. Clin Infect Dis 2000, 31:347-382.
5. Delvaeye M, Conway EM: Coagulation and innate immune responses: can we view them separately? Blood 2009, 114:2367-2374.
6. Levi M, van der Poll T: Inflammation and coagulation. Crit Care Med 2010, 38:S26-S34.
7. Engelmann B, Massberg S: Thrombosis as an intravascular effector of innate immunity. Nat Rev Immunol 2013, 13:34-45.
8. Esmon CT: Inflammation and the activated protein C anticoagulant pathway. Semin Thromb Hemost 2006, 32(Suppl 1):49-60.
9. Mosnier LO, Zlokovic BV, Griffin JH: The cytoprotective protein C pathway. Blood 2007, 109:3161-3172.
10. Fisher CJ Jr, Yan SB: Protein C levels as a prognostic indicator of outcome in sepsis and related diseases. Crit Care Med 2000, 28:S49-S56.
11. Shaw AD, Vail GM, Haney DJ, Xie J, Williams MD: Severe protein C deficiency is associated with organ dysfunction in patients with severe sepsis. J Crit Care 2011, 26:539-545.
12. Choi G, Schultz MJ, Levi M, van der Poll T, Millo JL, Garrard CS: Protein C in pneumonia. Thorax 2005, 60:705-706.
13. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher CJ Jr: Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001, 344:699-709.
14. Ely EW, Laterre PF, Angus DC, Helterbrand JD, Levy H, Dhainaut JF, Vincent JL, Macias WL, Bernard GR: Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis. Crit Care Med 2003, 31:12-19.
15. Opal SM, Garber GE, LaRosa SP, Maki DG, Freebairn RC, Kinasewitz GT, Dhainaut JF, Yan SB, Williams MD, Graham DE, Nelson DR, Levy H, Bernard GR: Systemic host responses in severe sepsis analyzed by causative microorganism and treatment effects of drotrecogin alfa (activated). Clin Infect Dis 2003, 37:50-58.
16. Marti-Carvajal AJ, Sola I, Lathyris D, Cardona AF: Human recombinant activated protein C for severe sepsis. Cochrane Database Syst Rev 2011, 3:CD004388.
17. Ranieri VM, Thompson BT, Barie PS, Dhainaut JF, Douglas IS, Finfer S, Gårdlund B, Marshall JC, Rhodes A, Artigas A, Payen D, Tenhunen J, Al-Khalidi HR, Thompson V, Janes J, Macias WL, Vangerow B, Williams MD, PROWESS-SHOCK Study Group: Drotrecogin alfa (activated) in adults with septic shock. N Engl J Med 2012, 366:2055-2064.
18. Mitka M: Drug for severe sepsis is withdrawn from market, fails to reduce mortality. JAMA 2011, 306:2439-2440.
19. Schouten M, van 't Veer C, Van Den Boogaard FE, Gerlitz B, Grinnell BW, Roelofs JJ, Roelofs JJ, Levi M, van der Poll T: Therapeutic recombinant murine activated protein C attenuates pulmonary coagulopathy and improves survival in murine pneumococcal pneumonia. J Infect Dis 2010, 202:1600-1607.
20. Schouten M, van 't Veer C, Roelofs JJ, Gerlitz B, Grinnell BW, Levi M, van der Poll T: Recombinant activated protein C attenuates coagulopathy and inflammation when administered early in murine pneumococcal pneumonia. Thromb Haemost 2011, 106:1189-1196.
21. Isermann B, Vinnikov IA, Madhusudhan T, Herzog S, Kashif M, Blautzik J, Corat MA, Zeier M, Blessing E, Oh J, Gerlitz B, Berg DT, Grinnell BW, Chavakis T, Esmon CT, Weiler H, Bierhaus A, Nawroth PP: Activated protein C protects against diabetic nephropathy by inhibiting endothelial and podocyte apoptosis. Nat Med 2007, 13:1349-1358.
22. Kager LM, Wiersinga WJ, Roelofs JJ, de Boer OJ, Meijers JC, Isermann B, van't Veer C, Van der Poll T: Overexpression of Activated Protein C is Detrimental During Severe Experimental Gram-Negative Sepsis (Melioidosis)*. Crit Care Med 2013, 41:e266-e274.
23. Kager LM, Wiersinga WJ, Roelofs JJ, Meijers JC, Zeerleder SS, Esmon CT, van der Poll T: Endogenous protein C has a protective role during Gram-negative pneumosepsis (melioidosis). J Thromb Haemost 2013, 11:282-292.
24. Schouten M, van't Veer C, Roelofs JJ, Levi M, van der Poll T: Protease-activated receptor-1 impairs host defense in murine pneumococcal pneumonia: a controlled laboratory study. Crit Care 2012, 16:R238.
25. Kalil AC, Florescu DF: Severe sepsis: are PROWESS and PROWESS-SHOCK trials comparable? A clinical and statistical heterogeneity analysis. Crit Care 2013, 17:167.
26. Opal SM, LaRosa SP: Recombinant human activated protein C as a therapy for severe sepsis: lessons learned? Am J Respir Crit Care Med 2013, 187:1041-1043.
27. Holder AL, Huang DT: A dream deferred: the rise and fall of recombinant activated protein C. Crit Care 2013, 17:309.
28. van der Poll T, de Boer JD, Levi M: The effect of inflammation on coagulation and vice versa. Curr Opin Infect Dis 2011, 24:273-278.
29. Macias WL, Dhainaut JF, Yan SC, Helterbrand JD, Seger M, Johnson G, Small DS: Pharmacokinetic-pharmacodynamic analysis of drotrecogin alfa (activated) in patients with severe sepsis. Clin Pharmacol Ther 2002, 72:391-402.
30. Elphick GF, Sarangi PP, Hyun YM, Hollenbaugh JA, Ayala A, Biffl WL, Chung HL, Rezaie AR, McGrath JL, Topham DJ, Reichner JS, Kim M: Recombinant human activated protein C inhibits integrin-mediated neutrophil migration. Blood 2009, 113:4078-4085.
31. Slofstra SH, Groot AP, Maris NA, Reitsma PH, Cate HT, Spek CA: Inhalation of activated protein C inhibits endotoxin-induced pulmonary inflammation in mice independent of neutrophil recruitment. Br J Pharmacol 2006, 149:740-746.
32. Abraham E: Effects of recombinant human activated protein C in human models of endotoxin administration. Proc Am Thorac Soc 2005, 2:243-247.
33. Galley HF, El Sakka NE, Webster NR, Lowes DA, Cuthbertson BH: Activated protein C inhibits chemotaxis and interleukin-6 release by human neutrophils without affecting other neutrophil functions. Br J Anaesth 2008, 100:815-819.
34. Kirschenbaum LA, Lopez WC, Ohrum P, Tsen A, Khazin J, Astiz ME: Effect of recombinant activated protein C and low-dose heparin on neutrophil-endothelial cell interactions in septic shock. Crit Care Med 2006, 34:2207-2212.
35. Nick JA, Coldren CD, Geraci MW, Poch KR, Fouty BW, O'Brien J, Gruber M, Zarini S, Murphy RC, Kuhn K, Richter D, Kast KR, Abraham E: Recombinant human activated protein C reduces human endotoxin-induced pulmonary inflammation via inhibition of neutrophil chemotaxis. Blood 2004, 104:3878-3885.
36. Braach N, Frommhold D, Buschmann K, Pflaum J, Koch L, Hudalla H, Staudacher K, Wang H, Isermann B, Nawroth P, Poeschl J: RAGE controls activation and anti-inflammatory signalling of protein C. PLoS One 2014, 9:e89422.
37. Curry FR, Adamson RH: Tonic regulation of vascular permeability. Acta Physiol (Oxf ) 2013, 207:628-649.
38. Feistritzer C, Riewald M: Endothelial barrier protection by activated protein C through PAR1-dependent sphingosine 1-phosphate receptor-1 crossactivation. Blood 2005, 105:3178-3184.